How many patents does
Albireo have?
patents
296
families
23
granted
72
applications
224
US
46
EP
35
CN
15
KR
10
WO
8
JP
5
RoW
177
Buy the report
The report contains ten-year analysis with the following sections
- patent filing analysis
- worldwide filing analysis
- patent family analysis
- application analysis
- granted analysis
- classification analysis
- citation analysis
contact us for pricing
- VAT will apply to UK companies
- EU companies must supply their VAT number
Check out our sample pages |
Find companies to compare
Many companies now available
companies
12,000+
patents
42 million
patent families
23 million
Search to find companies of interest
read summary of their published patent
the following tables are just extracts from the report
the company report contains more information
Albireo
Top ten assignees appearing on patents
2009 - 2018
| albireo | 221 |
| elobix | 27 |
| astrazeneca | 20 |
| dahlstrom, mikael, ulf, johan | 5 |
| al'biero | 1 |
| astrazeneca uk | 1 |
| ferring | 1 |
2009
| albireo | 36 |
| astrazeneca | 5 |
| dahlstrom, mikael, ulf, johan | 2 |
2018
| albireo | 30 |
| elobix | 1 |
| dahlstrom, mikael, ulf, johan | 1 |
Albireo
The top ten patent families are
|
Title of patent family (most common patent title) |
Family members |
Filing year |
|---|---|---|
| ibat inhibitors for the treatment of liver diseases | 60 | 2010 |
| crystal modifications of elobixibat | 34 | 2013 |
| a pharmaceutical combination comprising an ibat inhibitor and a bile acid binder | 30 | 2010 |
| 1- [ (4- [benzoyl (methyl) amino]-3- (phenyl) butyl]azetidine derivatives for the treatm… 🛈 | 24 | 2006 |
| 3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel … 🛈 | 22 | 2007 |
| use of an ibat inhibitor for the treatment or prophylaxis of constipation | 22 | 2003 |
| 1,5 benzothiazepines and their use as antihyperlipidemics | 13 | 2000 |
| 3-heterocyclyl-azetidine compounds useful as nk1/nk2 receptors antagonists | 12 | 2003 |
| ibat inhibitors for treatment of metabolic disorders and related conditions | 11 | 2010 |
| crystal modifications of elobixibat | 10 | 2014 |